Biogen (BIIB) Stock Forecast & Price Target

$143.32 -1.54 (-1.06%)

Closing price 09/15/2025 04:00 PM Eastern

Extended Trading

$144.66 +1.34 (+0.93%)

As of 09/15/2025 07:56 PM Eastern

Compare

Biogen - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Hold

Based on 31 Analyst Ratings

Sell
0

Hold
21

Buy
10

Based on 31 Wall Street analysts who have issued ratings for Biogen in the last 12 months, the stock has a consensus rating of "Hold." Out of the 31 analysts, 21 have given a hold rating, and 10 have given a buy rating for BIIB.

Consensus Price Target

$181.65
26.75% Upside

According to the 31 analysts' twelve-month price targets for Biogen, the average price target is $181.65. The highest price target for BIIB is $275.00, while the lowest price target for BIIB is $118.00. The average price target represents a forecasted upside of 26.75% from the current price of $143.32.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for BIIB and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Biogen and its competitors.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BIIB Analyst Ratings Over Time

Type	Current Forecast 9/16/24 to 9/16/25	1 Month Ago 8/17/24 to 8/17/25	3 Months Ago 6/18/24 to 6/18/25	1 Year Ago 9/17/23 to 9/16/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	10 Buy rating(s)	11 Buy rating(s)	12 Buy rating(s)	17 Buy rating(s)
Hold	21 Hold rating(s)	21 Hold rating(s)	20 Hold rating(s)	8 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$181.65	$185.74	$188.19	$275.52
Forecasted Upside	26.75% Upside	34.01% Upside	48.72% Upside	38.05% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

BIIB Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

BIIB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Biogen Stock vs. The Competition

Type	Biogen	Medical Companies	S&P 500
Consensus Rating Score	2.32	2.78	2.53
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	26.75% Upside	17,866.41% Upside	11.25% Upside
News Sentiment Rating	Positive News See Recent BIIB News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
9/4/2025	Needham & Company LLC 2 of 5 stars	Ami Fadia 5 of 5 stars	Reiterated Rating	Hold
8/14/2025	Piper Sandler 2 of 5 stars	David Amsellem Not Rated	Boost Target	Neutral	$115.00 ➝ $118.00	-11.71%
8/1/2025	Citigroup 2 of 5 stars	Geoff Meacham Not Rated	Boost Target	Neutral	$125.00 ➝ $135.00	+2.31%
8/1/2025	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$208.00 ➝ $219.00	+73.42%
8/1/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$146.00 ➝ $144.00	+15.25%
8/1/2025	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Fein Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Buy	$187.00 ➝ $194.00	+51.56%
7/21/2025	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Hold	$142.00	+14.61%
6/12/2025	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Laura Chico Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$121.00	-8.77%
5/7/2025	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salim Syed Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$207.00 ➝ $169.00	+44.55%
5/5/2025	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$185.00 ➝ $175.00	+42.11%
Get the Latest News and Ratings for BIIB and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.
5/2/2025	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jay Olson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$205.00	+68.31%
5/2/2025	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sumant Kulkarni Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$265.00 ➝ $220.00	+78.51%
5/2/2025	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Skorney Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$300.00 ➝ $255.00	+110.87%
4/28/2025	HSBC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$118.00	-0.71%
4/28/2025	Hsbc Global Res Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	M. Herholdt Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
4/23/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salveen Richter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$219.00 ➝ $197.00	+63.72%
4/4/2025	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jasper Hellweg Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold
2/13/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	George Farmer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Sector Outperform	$244.00 ➝ $224.00	+61.69%
2/13/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	E. Seigerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Market Perform	$156.00 ➝ $139.00	+1.30%
2/13/2025	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mohit Bansal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Equal Weight	$165.00 ➝ $140.00	+4.40%
2/11/2025	Bank Of America (Bofa) Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Neutral	$178.00 ➝ $163.00	+16.94%
2/11/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	R. Gal Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Market Perform	$160.00	+12.25%
1/13/2025	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Outperform
12/16/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$175.00	+16.64%
12/10/2024	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Neutral	$178.00	+13.77%
12/9/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Buy ➝ Hold	$250.00 ➝ $180.00	+14.08%
11/15/2024	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	A. Hammond Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Peer Perform
10/31/2024	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Equal Weight	$190.00 ➝ $180.00	+2.18%
10/31/2024	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$300.00 ➝ $275.00	+56.24%
10/10/2024	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Market Perform
10/3/2024	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	A. Verma Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$234.00 ➝ $202.00	+9.42%
9/9/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Overweight	$292.00 ➝ $292.00	+46.34%
1/7/2024	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	T. Shrader Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 02:56 AM ET.

Should I Buy Biogen Stock? BIIB Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 12, 2025. Please send any questions or comments about these Biogen pros and cons to contact@marketbeat.com.

Biogen
Bull Case

Here are some ways that investors could benefit from investing in Biogen Inc.:

Biogen Inc. recently reported strong quarterly earnings, with earnings per share significantly exceeding analysts' expectations, indicating robust financial health and operational efficiency.
The stock has a favorable price-to-earnings (P/E) ratio, suggesting that it may be undervalued compared to its earnings potential, which can attract value-focused investors.
Analysts have recently upgraded their ratings on Biogen Inc., with several firms raising their price targets, reflecting positive sentiment and potential for stock appreciation.
The current stock price is around $141, which is considered reasonable given the company's strong market position and growth prospects in the biotechnology sector.
Biogen Inc. has a solid market capitalization, indicating stability and the ability to invest in research and development for innovative therapies.

Biogen
Bear Case

Investors should be bearish about investing in Biogen Inc. for these reasons:

Despite recent positive earnings, the stock has experienced fluctuations, which may indicate volatility and risk for investors looking for stable returns.
There is a significant percentage of institutional ownership, which can lead to less price stability as large investors may sell off shares quickly in response to market changes.
Biogen Inc. faces intense competition in the biotechnology field, which could impact its market share and profitability in the long term.
The company has a relatively low insider ownership percentage, which may raise concerns about alignment between management and shareholder interests.
Recent market trends show a cautious approach towards biotechnology stocks, which could affect investor sentiment and stock performance in the near term.

BIIB Forecast - Frequently Asked Questions

: According to the research reports of 31 Wall Street equities research analysts, the average twelve-month stock price forecast for Biogen is $181.65, with a high forecast of $275.00 and a low forecast of $118.00.
: 31 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 21 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BIIB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BIIB, but not buy additional shares or sell existing shares.
: According to analysts, Biogen's stock has a predicted upside of 26.75% based on their 12-month stock forecasts.
: Biogen has been rated by research analysts at Citigroup, HC Wainwright, Morgan Stanley, Needham & Company LLC, Piper Sandler, Royal Bank Of Canada, and Truist Financial in the past 90 days.
: Analysts like Biogen less than other "medical" companies. The consensus rating for Biogen is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BIIB compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NASDAQ:BIIB) was last updated on 9/16/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biogen (BIIB) Stock Forecast & Price Target